汉森制药10月16日获融资买入291.50万元，融资余额1.51亿元

Group 1 - The core viewpoint of the news is that Hansoh Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant financing balances and a slight decline in net profit [1][2]. Group 2 - On October 16, Hansoh Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 33.34 million yuan. The financing buy-in amount was 2.92 million yuan, while the financing repayment was 4.74 million yuan, resulting in a net financing buy-in of -1.83 million yuan [1]. - As of October 16, the total financing and securities lending balance for Hansoh Pharmaceutical was 151 million yuan, with the financing balance accounting for 4.61% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, there were no shares repaid or sold on October 16, with the securities lending balance also at 0.00 shares, reflecting a high level compared to the past year [1]. Group 3 - Hansoh Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The main revenue sources for Hansoh Pharmaceutical include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and others, with a diverse product portfolio [2]. - As of August 29, the number of shareholders for Hansoh Pharmaceutical was 23,600, a decrease of 3.43% from the previous period, while the average circulating shares per person increased by 3.55% to 21,113 shares [2]. Group 4 - For the first half of 2025, Hansoh Pharmaceutical achieved an operating income of 509 million yuan, representing a year-on-year growth of 5.91%, while the net profit attributable to the parent company was 68.54 million yuan, a decrease of 31.80% year-on-year [2]. Group 5 - Since its A-share listing, Hansoh Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3].